Immune Checkpoint Blockade: Blocking Antibodies


Fig. 1 Schematic Diagram of immune checkpoint blockade

Immune checkpoints blockade can be a good way for cancer therapy because immune checkpoints act importantly in immunity to cancers. Thus it is significant to take advantages of blocking antibodies on the market to identify more checkpoint targets for cancer therapy.
PD1/PDCD1/CD279 is a T-cell surface protein, with inhibitory activaty when meeting with PD-L1/B7-H1/CD274. Some cancer cells can express increased PD-L1/B7-H1/CD274 to interact with PD1/PDCD1/CD279 and avoid immunity. So immune checkpoint blockade with PD1/PDCD1/CD279 and PD-L1/B7-H1/CD274 blocking antibodies can be a good way for cancer therapy.

Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking Antibodies
Immune Checkpoint Blockade: PD1 / PDCD1 / CD279 Blocking Antibodies

Immune Checkpoint Blockade: Validated Blocking Antibodies

Blocking assay of PD1 antibodies

Fig. 1 Immune checkpoint blockage assay of PD1 / PDCD1 / CD279 Blocking Antibody (10377-mhT28).
Blocking assay of PD-L1 antibodies

Fig. 1 Immune checkpoint blockage assay of PD-L1 / B7-H1 / CD274 Blocking Antibody (10084-R639).